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Abstract: 
 
Deferred active treatment (DAT) strategies, including active surveillance and active 
monitoring, are a recognised management option for men with localised low-risk 
prostate cancer. However, because of heterogeneity in the literature, there are 
uncertainties regarding the optimum criteria for patient selection, and the optimum 
constitution and scheduling of follow-up, monitoring characteristics, reclassification 
thresholds, and which outcome measures should be prioritised. This protocol 
describes a study led by the European Association of Urology (EAU) Prostate Cancer 
Guidelines Panel in conjunction with other guideline organisations and patient 
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advocacy groups* to develop consensus statements for all domains of deferred 
active treatment. The project is divided into 3 sequential phases: (1) Systematic 
review of studies reporting on DAT in order to summarise and define range of 
heterogeneity regarding all domains; (2) Two-round Delphi online survey involving a 
large, international multidisciplinary panel of healthcare professionals (HCPs) and 
patients to initiate consensus; and (3) Consensus group meeting involving 
representatives from HCP and patient stakeholder groups to finalise the consensus 
process. The consensus statements are expected to be adopted by clinical practice 
guidelines in order to standardise and guide practice for clinicians and researchers 
until better evidence emerges. 
Patient summary: We describe a project aimed at standardising elements of practice 
in active surveillance/monitoring for early localised prostate cancer, because 
currently there is great variation and uncertainty regarding how best to conduct them. 
This will be achieved through a structured process of agreement (i.e. consensus) 
amongst a large, international panel of healthcare professionals and patients.     
 
 
Deferred active treatment (DAT) strategies for men with localised prostate cancer 
have emerged as a viable alternative to radical intervention as we aim to avoid the 
consequences of over-treatment. Nevertheless, such strategies remain controversial, 
with significant uncertainty and heterogeneity in all domains, including criteria on 
patient selection, nature and timing of interventions during follow-up, criteria and 
thresholds for reclassification, and which outcome measures should be prioritised1-3. 
These are important barriers to the conduct and uptake of DAT by clinicians and 
patients as they prohibit the comparison of the clinical effectiveness of different 
protocols. In order to address these issues in a comprehensive, robust and 
systematic manner, the EAU Prostate Cancer Guidelines Panel, in partnership with 
other leading guideline authorities and organisations*, has commissioned a project to 
develop consensus statements in all domains relating to DAT in order to standardise 
clinical practice and research.  
 
The specific objectives are to achieve consensus on the following domains: (1) 
Criteria on patient selection (including patient and disease characteristics, imaging 
criteria and type of biopsies); (2) Nature and timing of investigations and 
assessments during follow-up (such as repeat imaging and repeat biopsies); (3) 
Criteria and thresholds for reclassification; and (4) Type of outcome measures which 
should be prioritised.  
 
To address these objectives, we will utilise transparent consensus methods involving 
a large, international cohort of stakeholders, broadly divided into two groups: (1) 
Healthcare professionals (HCPs) consisting of urologists, clinical or radiation 
oncologists, medical oncologists, radiologists, pathologists, primary care physicians,  
and nurse specialists; and (2) Patients.  The research will be divided into 3 distinct 
but inter-related phases, and is expected to last 12 months.   
 
Phase 1 is a systematic review conducted according to PRISMA guidelines4. The 
aim is to describe, explore and assess clinical heterogeneity in DAT studies which 
will inform the statements for the consensus processes. The review protocol has 
been published5. In brief, all prospective single-arm case series of DAT (including 
active surveillance and active monitoring but excluding watchful waiting), and all 
prospective comparative studies involving DAT will be included. The review will 
summarise eligibility and selection criteria, characteristics of monitoring and follow-up 
(including the type, frequency and timing of repeat imaging and repeat biopsies), 
reclassification definitions and thresholds, and primary outcomes measured in 
studies. English language articles published after 1990 will be included. Summary of 
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findings tables including details of the pre-specified domains and sub-domains will be 
developed. From these tables, a list of statements organised according to the 
different domains and sub-domains relating to all aspects of DAT will be generated. 
 
Phase 2 will comprise of a two-round online Delphi survey involving a large, 
international cohort of key stakeholders (HCPs and patients). The consensus 
methods used have been described previously in consensus studies in prostate 
cancer6,7. HCPs involved with DAT identified through international specialist 
societies* will be invited to participate. Patients throughout Europe with localised 
prostate cancer and eligible for DAT will be recruited through patient advocacy 
organisations*. Up to 150 HCPs and 50 patients will be invited to participate. Patients 
will be asked to complete the patient-relevant parts of the survey only (i.e. 
identification of most important outcomes). Participants will be asked to vote based 
on their level of agreement, on a nine-point scale, ranging from strongly disagree (1) 
to strongly agree (9) (i.e. 1–3 disagree; 4–6 uncertain; 7–9 agree). There will also be 
an ‘Unable to answer’ option. An online questionnaire will be developed for the 
Delphi process using COMET Initiative DelphiManager8. Two iterative rounds will be 
conducted anonymously, with anonymised feedback provided to all participants at 
the end of each round showing the percent scoring at each response option. In 
Round 1, participants will have the opportunity to add further statements for 
incorporation into Round 2. With an anticipated response rate of 80% for both 
stakeholder groups, and expected overall completion rate of 80%, the total number of 
participants involved is expected to be at least 128 (i.e. 96 HCPs and 32 patients). 
The results for each stakeholder group will be analysed and presented separately in 
each round. After the final round, statements scoring ‘strongly agree’ (i.e. 7–9) by 
≥70% of participants AND with minimal disagreement scored by the rest (defined as 
<15% of participants scoring ‘strongly disagree’ i.e. 1-3) will be considered as 
reaching the threshold for ‘consensus agree’. Conversely, statements scoring 
‘strongly disagree’ (i.e. 1-3) by ≥70% of participants AND with minimal agreement 
scored by the rest (defined as <15% of participants scoring ‘strongly agree’ i.e. 7-9) 
will be considered as reaching the threshold for ‘consensus disagree’. All other 
statements not falling in the above categories will be classified as ‘equivocal’. 
Statements reaching consensus (either agree or disagree) will be collated for review 
in Phase 3, whilst equivocal statements will be brought forward for discussion and 
voting in Phase 3. 
 
Phase 3 is the final stage of the consensus process, involving a 1-day meeting 
attended by representatives of each stakeholder group and chaired by a non-voting 
methodologist and a clinician moderator. We will use structured discussion and live 
voting sessions. Representatives from each stakeholder groups and sub-groups (i.e. 
urologists, oncologists, radiologists, pathologists and patients) will be purposively 
sampled from those completing all rounds of the Delphi survey to ensure proportional 
representation. The voting panel will consist of 25 voting participants (i.e. 7 patients 
and 18 HCPs). Statements reaching consensus (either agree or disagree) from 
Phase 2 will be reviewed by the panel. Consensus decisions from the Delphi survey 
cannot be overturned by the panel without sound reasoning (e.g. misleading 
statements). Equivocal statements from Phase 2 will be discussed and voted on by 
the panel. Scoring thresholds will be the same as Phase 2 (i.e. level of agreement on 
a nine-point scale: 1–3 disagree; 4–6 uncertain; 7–9 agree; and ‘Unable to answer’). 
Voting will be anonymous using Poll Everywhere9 which participants can access 
during the meeting using personal computers and a shared IP address. Definitions of 
consensus will be the same as in Phase 2. Results for all statements will be 
conveyed in real-time, and final consensus statements will be prepared. A final list of 
consensus statements organised according to the domains and sub-domains of DAT 
will be issued.  
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The consensus statements are expected to be adopted by guideline developers and 
disseminated through clinical practice guidelines issued by the EAU Prostate Cancer 
Guidelines Panel and other organisations*, and are intended to provide authoritative 
guidance to clinicians and researchers by standardising definitions, thresholds, 
terminology and characteristics of patient selection, monitoring, reclassification and 
change in management, and outcome measures which should be prioritised in 
programmes of deferred active treatment in clinical practice and research, at least 
until higher levels of evidence emerge such as from the GAP3 initiative10.  
 
* The list of official collaborators include the following organisations and patient advocacy groups:  
 
European Association of Urology (EAU) 
European Association of Urology Nurses (EAUN) 
EAU PIONEER  
European Urology Editorial Board 
American Urological Association (AUA) 
Canadian Urological Association (CUA) 
European Society for Radiotherapy and Oncology (ESTRO) 
International Society of Urological Pathology (ISUP) 
Urological Society of Australia and New Zealand (USANZ) 
European Society of Urogenital Radiology (ESUR) 
EAU Section of Oncological Urology (ESOU) 
Urological Association of Asia (UAA) 
American Society for Radiation Oncology (ASTRO) 
American Society of Clinical Oncology (ASCO) 
European Forum for Primary Care (EFPC) 
EAU Research Foundation (EAU RF) 
UCAN UK 
Tackle Prostate Cancer UK 
Europa UOMO  
Movember Foundation 
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